

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**NOVARTIS**

2. Address:

701 PENNSYLVANIA AVENUE, NW, #725, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: ANDREA MCCABE

Telephone: 2026387429

E-mail (optional): andrea.mccabe@novartis.com

Senate ID #: 9204-12

House ID #: 33589000

7. Client Name:  Self

## TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: Dec 30, 1899 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 3,460,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: NOVARTIS Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

DoD Authorization language - Section 701, Dealing with TriCare H.R. 2764 Consolidated Approps Bill - Pandemic Influenza Funding  
H.R. 3222 DoD Approps Bill - TMTI Program Funding H.R. 4156 FY '08 Iraq Supplemental Bill - Pandemic Influenza

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH  
Covered Official Position (if applicable): N/A  
Name: CASSERLY, DANIEL  
Covered Official Position (if applicable): N/A  
Name: DRAKE, DAVID  
Covered Official Position (if applicable): N/A  
Name: ELKIN, JAMES  
Covered Official Position (if applicable): N/A  
Name: GILES, THOMAS  
Covered Official Position (if applicable): N/A  
Name: HALLER, SARAH E.  
Covered Official Position (if applicable): N/A  
Name: HUGHES, GENE  
Covered Official Position (if applicable): N/A  
Name: SOLON, KATHERINE  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS Client Name: Self

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S.1145 Patent Reform Act of 2007 H.R.1908 Patent Reform Act of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CASSERLY, DANIEL

Covered Official Position (if applicable): N/A

Name: DRAKE, DAVID

Covered Official Position (if applicable): N/A

Name: ELKIN, JAMES

Covered Official Position (if applicable): N/A

Name: GILES, THOMAS

Covered Official Position (if applicable): N/A

Name: SOLON, KATHERINE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R. 970 and S. 1378 - Dextromethorphan Distribution Act of 2007 S. 3678 Pandemic All Hazards Preparedness Act (Biodefense) S. 103  
Combat Meth Act of 2005 H.R. 2206 - Supplemental Appropriations

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH

Covered Official Position (if applicable): N/A

Name: CASSERLY, DANIEL

Covered Official Position (if applicable): N/A

Name: DRAKE, DAVID

Covered Official Position (if applicable): N/A

Name: ELKIN, JAMES

Covered Official Position (if applicable): N/A

Name: GILES, THOMAS

Covered Official Position (if applicable): N/A

Name: HALLER, SARAH E.

Covered Official Position (if applicable): N/A

Name: HUGHES, GENE

Covered Official Position (if applicable): N/A

Name: SOLON, KATHERINE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

S. 2029 Physician Payments Sunshine Act of 2007 H.R. 6111 Tax Relief and health Care Act (Medicare) Access to Life Saving Medicines Act Medicare Part B and Part D - Part D: Non-Interference Part B: Prompt Pay Removal from ASP Calculation

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH  
Covered Official Position (if applicable): N/A  
Name: CASSERLY, DANIEL  
Covered Official Position (if applicable): N/A  
Name: DRAKE, DAVID  
Covered Official Position (if applicable): N/A  
Name: ELKIN, JAMES  
Covered Official Position (if applicable): N/A  
Name: GILES, THOMAS  
Covered Official Position (if applicable): N/A  
Name: HALLER, SARAH E.  
Covered Official Position (if applicable): N/A  
Name: HUGHES, GENE  
Covered Official Position (if applicable): N/A  
Name: SOLON, KATHERINE  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Free Trade Agreements: - Peru, Columbia, Korea and Intellectual Property Issues USTR

17. House(s) of Congress and Federal agencies contacted:

Commerce, Dept of (DOC)

HOUSE OF REPRESENTATIVES

SENATE

U.S. Agency for International Development (USAID)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ARON, RENARD

Covered Official Position (if applicable): N/A

Name: HALLER, SARAH E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: ANDREA L. MCCABE, ADMINISTRATI -

Registrant Name: NOVARTIS Client Name: Self

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Feb 14, 2008

Printed Name and Title: -